Publication:
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

Issued Date

2004-08-15

Resource Type

Article

ISSN

00221899

DOI

10.1086/422258

Other identifier(s)

2-s2.0-20244383550

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Journal of Infectious Diseases. Vol.190, No.4 (2004), 702-706

Suggested Citation

Sorachai Nitayaphan, Punnee Pitisuttithum, Chitraporn Karnasuta, Chirapa Eamsila, Mark De Souza, Patricia Morgan, Victoria Polonis, Michael Benenson, Tom VanCott, Silvia Ratto-Kim, Jerome Kim, Darawan Thapinta, Robin Garner, Valai Bussaratid, Pricha Singharaj, Raphaelle El Habib, Sanjay Gurunathan, William Heyward, Deborah Birx, John McNeil, Arthur E. Brown Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. Journal of Infectious Diseases. Vol.190, No.4 (2004), 702-706. doi:10.1086/422258 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/21582

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults

Author(s)

Sorachai Nitayaphan
 Punnee Pitisuttithum
 Chitraporn Karnasuta
 Chirapa Eamsila
 Mark De Souza
 Patricia Morgan
 Victoria Polonis
 Michael Benenson
 Tom VanCott
 Silvia Ratto-Kim
 Jerome Kim
 Darawan Thapinta
 Robin Garner
 Valai Bussaratid
 Pricha Singharaj
 Raphaelle El Habib
 Sanjay Gurunathan
 William Heyward
 Deborah Birx
 John McNeil
 Arthur E. Brown

Other Contributor(s)

Mahidol University
 Chiang Mai University
 Walter Reed Army Institute of Research
 Sanofi Pasteur SA
 VaxGen, Inc.
 Armed Forces Research Institute of Medical Sciences, Thailand
 Leahi Hospital
 Tripler Regional Med Center
 National Institute of Allergy and Infectious Diseases

Abstract

ALVAC-HIV (vCP1521) and AIDSVAX B/E were evaluated in a phase 1/2 trial of human immunodeficiency virus (HIV)-negative Thai adults. Of 133 volunteers enrolled, 122 completed the trial. There were no serious vaccine-related adverse events, nor were there intercurrent HIV infections. Lymphoproliferative responses to glycoprotein 120 E were induced in 63% of the volunteers, and HIV-specific CD8 cytotoxic T lymphocyte responses were induced in 24%. Antibody responses increased in frequency and magnitude in association with the dose level of AIDSVAX B/E. Binding and neutralizing antibodies to the MN strain were induced in 100% and 98%, respectively, of the volunteers receiving 600 μg of AIDSVAX B/E, and such antibodies to E strains were induced in 96% and 71%, respectively, of these volunteers. This vaccine combination was well tolerated and was immunogenic, meeting milestones for advancement to phase 3 evaluation.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/21582

Collections

Scopus 2001-2005